When Cell and Gene Therapies Surge to Market, How Resilient Will Your Cell Sourcing Infrastructure Be?
Nullam velit nulla commodo sem, at egestas nulla metus vel imperdiet aptent taciti ad litora torquent per.
UK Review and Recommendations on the Procurement of Starting Materials by Apheresis for ATMP Manufacture
To ensure safe, high-quality Advanced Therapy Medicinal Products (ATMPs) are delivered to patients, procurement activities must be standardized when possible. Standardization also supports efficiency and reduces the risk for error while meeting regulatory and accreditation requirements. Download the UK Review and Recommendations on the Procurement of Starting Materials by Apheresis for ATMP Manufacture for insights…
The EBMT/EHA CAR-T Cell Handbook
A joint venture between the European Society of Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), the CAR-T Cell Handbook offers clinical care applications for health care professionals in the EU that treat patients with CAR-T cell therapies. Download the guide for insights into many aspects of CAR-T cell therapies including: The…
The Challenge of Multiple Audits and Redundant Training
As UCLA Health continues to participate in multiple CAR-T and other immunotherapy clinical trials, its apheresis unit and cell therapy lab continue to experience an increase in the need for their cell collection and processing services. Guest author, Heather Steinmetz, MPH, Quality Assurance Manager, UCLA Health Hematologic Malignancy/Stem Cell Transplant Program, shares some of the…
Strategies to Relieve the Burden on Apheresis & Collection Centers
As cell and gene therapies continue to progress at a rapid pace, apheresis and collection centers face the challenges of keeping up with demand, while maintaining high-quality levels. View this on-demand webinar for an in-depth discussion of standardization strategies that can bring efficiencies to the apheresis and collection infrastructure. Also included is a Q&A session…
Optimizing Access to High-Quality, Standardized and Compliant Leukopaks for the Development and Commercialization of Allogeneic Therapies
Cellular starting material is the most critical component in the allogeneic cell therapy manufacturing process. Ensuring material access while maintaining quality, consistency and regulatory compliance are necessary throughout every stage of clinical development through commercialization. During this webinar, you will learn about: Factors to ensure streamlined access to high-quality, consistent starting material for allogeneic therapies…
How Starting Material Quality Impacts the Manufacturing and Success of Next-Generation Therapies
This on-demand webinar helps answer the question, “What constitutes quality allogeneic cell therapy starting material and how you can ensure it?” The webinar explores specific risks and practical downstream repercussions of insufficient and variable starting material quality. Our expert panelists discuss how to help ensure both high-quality and consistent cellular starting material by building efficiencies…
Critical Components for Developing & Managing Expansive, High-Performing Collection Networks
A high-performing collection center network is essential to providing and delivering quality starting material for emerging cell and gene therapies. Learn about effective practices for building and maintaining collection networks in our on-demand webinar, Critical Components for Developing & Managing Expansive, High-Performing Collection Networks. Amy Hines, BSN, RN, director, Collection Network Management, Be The Match BioTherapies®,…
Considerations for Developing Scalable and Efficient Collection Network Processes
On-demand webinar offers actionable insights as you develop your protocols. Many crucial considerations impact a cell and gene therapy developer’s apheresis center selection strategy and ability to efficiently scale processes. When collection processes or protocols differ from those in place at a center, there are likely implications for training, forms and standard operating procedures. This…